Evaluating Vinpocetine for Diabetic Kidney Disease
The Effect of Vinpocetine on the Clinical Outcome of Patients With Diabetic Nephropathy
PHASE2; PHASE3 · Ain Shams University · NCT06441591
This study is testing if vinpocetine can help improve kidney function and overall health in people with diabetic kidney disease.
Quick facts
| Phase | PHASE2; PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 64 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ain Shams University (other) |
| Locations | 2 sites (Cairo, Abbasseia and 1 other locations) |
| Trial ID | NCT06441591 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to assess the effects of vinpocetine on patients with diabetic nephropathy. Participants will be randomly assigned to receive either vinpocetine or a placebo twice daily for three months. The study will evaluate various outcomes, including kidney function, glucose and lipid levels, inflammatory markers, and quality of life. The trial is particularly relevant given the high prevalence of diabetes and its complications, especially in regions like Egypt.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with type II diabetes and chronic kidney disease stages 3 or 4.
Not a fit: Patients with severe comorbidities, active malignancies, or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new therapeutic option for managing diabetic nephropathy and improving kidney health in diabetic patients.
How similar studies have performed: While vinpocetine has shown promise in other conditions, this specific application in diabetic nephropathy is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years, * Type II diabetic patients with CKD stage 3 (eGFR = 30 - 59 ml/min) or stage 4 (eGFR 15-29 ml/min), * Albumin/Creatinine ratio (ACR): 30 - 300 μg /mg (microalbuminuria), * Stable standard therapy for at least three months prior to inclusion in the study. Exclusion Criteria: * Kidney donor or recipient, * Active malignancy, * Pregnancy or breastfeeding, * Known intolerance or hypersensitivity to VPN, * Participation in other interventional trials, * Patients with inadequate liver function (ALT and AST three times greater than the upper normal limits), * Patients with severe comorbidities * Patients receiving warfarin
Where this trial is running
Cairo, Abbasseia and 1 other locations
- Ain Shams University Hospital — Cairo, Abbasseia, Egypt (NOT_YET_RECRUITING)
- Ain Shams Hospitals — Cairo, Abbasseya, Egypt (RECRUITING)
Study contacts
- Study coordinator: Tamer El Said
- Email: drtamer_elsaid@med.asu.edu.eg
- Phone: 201227366062
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Diabetic Kidney Disease, Diabetic Nephropathies, Vinpocetine, Diabetic nephropathy, diabetic kidney disease, UACR, ICAM